Discussing indemnity, other issues with foreign Covid vaccine makers: Govt

A team of central government officials is in continuous dialogue with foreign Covid vaccine manufactures like Pfizer, Moderna and Johnson and Johnson to discuss and address various issues, including indemnity, the Lok Sabha was informed on Friday.

Providing the present status of discussions with pharma companies like Pfizer and Moderna over giving them indemnity against cost of compensation for adverse effects due to vaccination, Union Minister Bharati Pravin Pawar in a written reply said the government constituted the team on June 11 to deal with various issues related to procurement of COVID-19 vaccine from foreign manufacturers.

"This team is in continuous dialogue with Pfizer, Moderna and Johnson and Johnson to discuss and address various issues including the issue of indemnity," , the minister of state for health said.

She clarified that no domestic manufacturer of Covid vaccine has demanded indemnity against adverse effects of vaccination.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel